Biotech Values

[DFRAI]

Well, since Marth made those comments about a month ago, there has been no motion by Teva for a summary judgment. Instead, we now know that Teva has been negotiating with NVS as to how much advance notice Teva will receive when NVS launches generic Copaxone. Novartis gave them 2 hrs advance notice

Why is this notable? Because there’s no way in hell NVS would launch without a favorable outcome to the patent case in the District Court. (NVS might launch at-risk prior to a decision by the appellate court, however.) In other words, Teva would have no reason to be concerned about receiving advance notice of NVS’ launch unless Teva thought they might lose the patent case.

So this Copaxone saga might come to a head early next year - assuming FDA approves Sandoz anda and there is favorable outcome on patent challenge in district court

I hope those 6.8 million shorts are reading this board....Nice inferences Dewdiligence.

Personally i hope to get another chance to add before year end at anyprice under 17, if certain items go my way and once we get a feel for sales/royalty income